High-Affinity Thrombin Aptamers for Targeted Thrombin Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current direct oral anticoagulants (DOACs) like dabigatran have limitations such as side effects, drug interactions, bleeding risks, and contraindications, necessitating the development of safer and more effective alternatives for treating thrombosis and related conditions.
Innovation Solution
Development of thrombin-specific aptamers, including sequences such as SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21, which can be used in pharmaceutical compositions with stabilizing moieties, and kits for treating thrombosis and adverse events from aptamer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct oral anticoagulants (DOACs) like dabigatran are used to treat thrombosis, then thrombin inhibition effectiveness is improved, but side effects and drug interactions increase
Solution Approach 1:
The patent uses aptamers as simplified copies of natural anticoagulant molecules that specifically target thrombin. These aptamers replicate the therapeutic effect of natural anticoagulants while avoiding the complex metabolic pathways that cause drug interactions, thus resolving the contradiction between effectiveness and safety
Solution Approach 2:
The patent modifies the chemical structure parameters of traditional anticoagulants by using nucleic acid-based aptamers instead of small molecule drugs. This fundamental parameter change allows for high specificity and affinity binding to thrombin while eliminating the metabolic enzyme interactions that cause adverse effects
2Reliability
If conventional anticoagulants are used to treat thrombosis, then thrombin inhibition is achieved, but monitoring complexity and dose adjustment requirements increase
Solution Approach 1:
The aptamers are designed with self-regulating properties where their binding affinity to thrombin automatically adjusts to therapeutic levels. The molecules naturally saturate thrombin binding sites without requiring external monitoring or dose adjustments, eliminating the need for frequent blood tests and physician interventions
3Ease of operation
If dabigatran is used as a thrombin inhibitor, then oral administration convenience is improved, but gastrointestinal side effects and throat irritation increase
Solution Approach 1:
The patent employs short-lived aptamer molecules that are rapidly cleared from the gastrointestinal tract after exerting their therapeutic effect. These disposable-like molecules provide transient protection against thrombosis without accumulating in the GI tract, thus avoiding chronic irritation while maintaining oral administration convenience
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers effectively inhibit thrombin activity, reducing thrombosis risk and ameliorating adverse events, with specific binding affinities and minimal side effects, as demonstrated by in vitro and ex vivo studies.
Implementation Method 1
The aptamers effectively inhibit thrombin activity, reducing thrombosis risk and ameliorating adverse events, with specific binding affinities
Data Source
AI summary
Disclosed are aptamers, aptamer antidotes, and their use in the treatment of thrombosis and other thrombotic conditions.